MedTrace Logo

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

NCT06274515 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2026-05-06

No results posted yet for this study

Summary

This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.

Conditions

Interventions

PROCEDURE

Tumor Tissue and Blood Draw

Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-02
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Belgium
  • Denmark
  • Finland
  • Germany
  • Italy
  • Norway
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06274515 on ClinicalTrials.gov